{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:34:56Z","timestamp":1792784096265,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"University of Wisconsin-Madison, School of Nursing","id":[{"id":"https:\/\/ror.org\/01y2jtd41","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s11883-020-00843-x","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T21:02:17Z","timestamp":1592254937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-6077","authenticated-orcid":false,"given":"Wan-chin","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Ersig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsan-Hua","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Bratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"issue":"2","key":"843_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes J-P, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136. https:\/\/doi.org\/10.1038\/ng1161.","journal-title":"Nat Genet"},{"issue":"4","key":"843_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s13167-017-0106-6","volume":"8","author":"M Wicinski","year":"2017","unstructured":"\u2022\u2022 Wicinski M, Zak J, Malinowski B, Popek G, Grzesk G. PCSK9 signaling pathways and their potential importance in clinical practice. EPMA J. 2017;8(4):391\u2013402. https:\/\/doi.org\/10.1007\/s13167-017-0106-6. A landmark review summarizing the biological mechanisms, functionality, and application of PCSK9 in lipid metabolism.","journal-title":"EPMA J"},{"issue":"9","key":"843_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.5551\/jat.RV17012","volume":"24","author":"T Nozue","year":"2017","unstructured":"Nozue T. Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb. 2017;24(9):895\u2013907. https:\/\/doi.org\/10.5551\/jat.RV17012.","journal-title":"J Atheroscler Thromb"},{"issue":"12","key":"843_CR4","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1194\/jlr.R026658","volume":"53","author":"G Lambert","year":"2012","unstructured":"Lambert G, Sjouke B, Choque B, Kastelein JJP, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53(12):2515\u201324. https:\/\/doi.org\/10.1194\/jlr.R026658.","journal-title":"J Lipid Res"},{"key":"843_CR5","doi-asserted-by":"publisher","unstructured":"\u2022 Shapiro MD, Tavori H, Fazio S. PCSK9: From basic science discoveries to clinical trials. Circ Res. 122(10):1420\u201338. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311227. A landmark review summarizing the biological mechanisms, functionality, and application of PCSK9 in lipid metabolism.","DOI":"10.1161\/CIRCRESAHA.118.311227"},{"issue":"11","key":"843_CR6","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","volume":"140","author":"DK Arnett","year":"2019","unstructured":"\u2022 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;140(11):e596\u2013646. https:\/\/doi.org\/10.1161\/CIR.0000000000000678. The latest guideline from ACC\/AHA on the primary prevention of cardiovascular disease.","journal-title":"Circulation"},{"issue":"3","key":"843_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1249\/MSS.0000000000001811","volume":"51","author":"ME Rosenberger","year":"2019","unstructured":"\u2022 Rosenberger ME, Fulton JE, Buman MP, Troiano RP, Grandner MA, Buchner DM, et al. The 24-hour activity cycle: A new paradigm for physical activity. Med Sci Sports Exerc. 2019;51(3):454\u201364. https:\/\/doi.org\/10.1249\/MSS.0000000000001811. A crucial article defining the model of 24-HAC and describing the application of 24-HAC in exercise research.","journal-title":"Med Sci Sports Exerc"},{"key":"843_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.vph.2016.10.003","volume":"87","author":"CH Saely","year":"2016","unstructured":"\u2022\u2022 Saely CH, Drexel H. Impact of diet and exercise on proprotein convertase subtilisin\/kexin 9: a mini-review. Vasc Pharmacol. 2016;87:10\u20133. https:\/\/doi.org\/10.1016\/j.vph.2016.10.003. The pioneering review summarizing the association between physical activity and PCSK9.","journal-title":"Vasc Pharmacol"},{"issue":"8","key":"843_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11883-016-0604-3","volume":"18","author":"BA Taylor","year":"2016","unstructured":"Taylor BA, Paul DT. Statins and their effect on PCSK9\u2014impact and clinical relevance. Curr Atheroscler Rep. 2016;18(8):46. https:\/\/doi.org\/10.1007\/s11883-016-0604-3.","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"843_CR10","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1194\/jlr.P009860","volume":"51","author":"JD Browning","year":"2010","unstructured":"Browning JD, Horton JD. Fasting reduces plasma proprotein convertase, subtilisin\/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res. 2010;51(11):3359\u201363. https:\/\/doi.org\/10.1194\/jlr.P009860.","journal-title":"J Lipid Res"},{"key":"843_CR11","doi-asserted-by":"publisher","unstructured":"Ruscica M, Ferri N, Fogacci F, Rosticci M, Botta M, Marchiano S, et al. Circulating levels of proprotein convertase subtilisin\/kexin type 9 and arterial stiffness in a large population sample: data from the Brisighella Heart Study. J Am Heart Assoc. 2017;6(5). https:\/\/doi.org\/10.1161\/JAHA.117.005764.","DOI":"10.1161\/JAHA.117.005764"},{"issue":"3","key":"843_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.pain.2005.06.018","volume":"117","author":"SL Yates","year":"2005","unstructured":"Yates SL, Morley S, Eccleston C, de C Williams AC. A scale for rating the quality of psychological trials for pain. Pain. 2005;117(3):314\u201325. https:\/\/doi.org\/10.1016\/j.pain.2005.06.018.","journal-title":"Pain"},{"key":"843_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"11","key":"843_CR14","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504. https:\/\/doi.org\/10.1101\/gr.1239303.","journal-title":"Genome Res"},{"key":"843_CR15","doi-asserted-by":"publisher","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Chapter 4: effect sizes based on means. Introduction to meta-analysis: John Wiley & Sons; 2009. Available from: https:\/\/onlinelibrary.wiley.com, https:\/\/doi.org\/10.1002\/9780470743386.ch4","DOI":"10.1002\/9780470743386.ch4"},{"key":"843_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fphys.2019.00456","volume":"10","author":"KA Makela","year":"2019","unstructured":"Makela KA, Leppaluoto J, Jokelainen J, Jamsa T, Keinanen-Kiukaanniemi S, Herzig K-H. Effect of physical activity on plasma PCSK9 in subjects with high risk for type 2 diabetes. Front Physiol. 2019;10:456. https:\/\/doi.org\/10.3389\/fphys.2019.00456.","journal-title":"Front Physiol"},{"key":"843_CR17","doi-asserted-by":"publisher","first-page":"908048","DOI":"10.1155\/2013\/908048","volume":"2013","author":"S Wen","year":"2013","unstructured":"Wen S, Jadhav KS, Williamson DL, Rideout TC. Treadmill exercise training modulates hepatic cholesterol metabolism and circulating PCSK9 concentration in high-fat-fed mice. J Lipids. 2013;2013:908048\u20139. https:\/\/doi.org\/10.1155\/2013\/908048.","journal-title":"J Lipids"},{"issue":"7","key":"843_CR18","doi-asserted-by":"publisher","first-page":"e0159550","DOI":"10.1371\/journal.pone.0159550","volume":"11","author":"ET Ngo Sock","year":"2016","unstructured":"Ngo Sock ET, Mayer G, Lavoie J-M. Combined effects of rosuvastatin and exercise on gene expression of key molecules involved in cholesterol metabolism in ovariectomized rats. PLoS One. 2016;11(7):e0159550. https:\/\/doi.org\/10.1371\/journal.pone.0159550.","journal-title":"PLoS One"},{"issue":"3","key":"843_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4149\/gpb_2017047","volume":"37","author":"Z Farahnak","year":"2018","unstructured":"Farahnak Z, Chapados N, Lavoie J-M. Exercise training increased gene expression of LDL-R and PCSK9 in intestine: link to transintestinal cholesterol excretion. Gen Physiol Biophys. 2018;37(3):309\u201317. https:\/\/doi.org\/10.4149\/gpb_2017047.","journal-title":"Gen Physiol Biophys"},{"issue":"6","key":"843_CR20","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.jacl.2016.08.014","volume":"10","author":"M Boyer","year":"2016","unstructured":"Boyer M, Levesque V, Poirier P, Marette A, Mathieu P, Despres J-P, et al. Impact of a 1-year lifestyle modification program on plasma lipoprotein and PCSK9 concentrations in patients with coronary artery disease. J Clin Lipidol. 2016;10(6):1353\u201361. https:\/\/doi.org\/10.1016\/j.jacl.2016.08.014.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"843_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2014.07.010","volume":"236","author":"BJ Arsenault","year":"2014","unstructured":"Arsenault BJ, Pelletier-Beaumont E, Almeras N, Tremblay A, Poirier P, Bergeron J, et al. PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program. Atherosclerosis. 2014;236(2):321\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.07.010.","journal-title":"Atherosclerosis."},{"issue":"7414","key":"843_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ."},{"key":"843_CR23","first-page":"198","volume-title":"Explaining heterogeneity among effect sizes: Moderator analysis. Applied meta-analysis for social science research. First","author":"NA Card","year":"2011","unstructured":"Card NA. Explaining heterogeneity among effect sizes: Moderator analysis. Applied meta-analysis for social science research. First. New York, NY: Guilford Press; 2011. p. 198\u2013228."},{"key":"843_CR24","unstructured":"Borenstein, M., Hedges, L. V., Higgins, J. P. T., Rothstein, H. R. Comprehensive Meta-Analysis Version 3 [Internet]. 2014. Available from: https:\/\/www.meta-analysis.com\/"},{"key":"843_CR25","doi-asserted-by":"publisher","unstructured":"Sponder M, Campean IA, Dalos D, Emich M, Fritzer-Szekeres M, Litschauer B, et al. Influence of long-term physical activity on serum PCSK9, HDL\/LDL-cholesterol and lipoprotein a-levels. Eur Heart J. 2017;38:315\u20135. https:\/\/doi.org\/10.20452\/pamw.4044.","DOI":"10.20452\/pamw.4044"},{"issue":"10","key":"843_CR26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/eci.12480","volume":"45","author":"CH Kamani","year":"2015","unstructured":"Kamani CH, Gencer B, Montecucco F, Courvoisier D, Vuilleumier N, Meyer P, et al. Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population. Eur J Clin Investig. 2015;45(10):1017\u201324. https:\/\/doi.org\/10.1111\/eci.12480.","journal-title":"Eur J Clin Investig"},{"key":"843_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.atherosclerosis.2019.02.015","volume":"284","author":"B Gencer","year":"2019","unstructured":"Gencer B, Pagano S, Vuilleumier N, Satta N, Delhumeau-Cartier C, Meier C, et al. Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naive of statin therapy: a cross-sectional analysis from the Swiss HIV cohort. Atherosclerosis. 2019;284:253\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.02.015.","journal-title":"Atherosclerosis."},{"issue":"12","key":"843_CR28","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","volume":"30","author":"L Persson","year":"2010","unstructured":"Persson L, Cao G, Stahle L, Sjoberg BG, Troutt JS, Konrad RJ, et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol. 2010;30(12):2666\u201372. https:\/\/doi.org\/10.1161\/ATVBAHA.110.214130.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"843_CR29","doi-asserted-by":"publisher","first-page":"1950010","DOI":"10.1142\/S0219519419500106","volume":"19","author":"Y Wei","year":"2019","unstructured":"Wei Y. Candidate genes and pathways linking sleep deprivation to obesity. J Mech Med Biol. 2019;19(3):1950010. https:\/\/doi.org\/10.1142\/S0219519419500106.","journal-title":"J Mech Med Biol"},{"issue":"5","key":"843_CR30","first-page":"5191","volume":"12","author":"J-F Zhao","year":"2019","unstructured":"Zhao J-F, Wang Y-X, Dong Y-K, Shi J-Z, Li H, Wu B-A. Aerobic exercise combined with samara oil can improve hyperlipidemia by reducing PCSK9 and increasing LDLR. Int J Clin Exp Med. 2019;12(5):5191\u20137.","journal-title":"Int J Clin Exp Med"},{"issue":"8","key":"843_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1055\/s-0034-1370910","volume":"46","author":"ET Ngo Sock","year":"2014","unstructured":"Ngo Sock ET, Chapados NA, Lavoie J-M. LDL receptor and Pcsk9 transcripts are decreased in liver of ovariectomized rats: effects of exercise training. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2014;46(8):550\u20135. https:\/\/doi.org\/10.1055\/s-0034-1370910.","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"843_CR32","doi-asserted-by":"crossref","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Chapter 30: publication bias. Introduction to meta-analysis. John Wiley & Sons, Ltd; 2009. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/9780470743386.ch30","DOI":"10.1002\/9780470743386"},{"issue":"1","key":"843_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","volume":"15","author":"RM Stoekenbroek","year":"2018","unstructured":"Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology beyond LDL control. Nat Rev Endocrinol. 2018;15(1):52\u201362. https:\/\/doi.org\/10.1038\/s41574-018-0110-5.","journal-title":"Nat Rev Endocrinol"},{"key":"843_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cca.2014.10.044","volume":"440","author":"C-J Cui","year":"2015","unstructured":"Cui C-J, Li S, Li J-J. PCSK9 and its modulation. Clin Chim Acta Int J Clin Chem. 2015;440:79\u201386. https:\/\/doi.org\/10.1016\/j.cca.2014.10.044.","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"843_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/1476-511X-13-188","volume":"13","author":"R-X Xu","year":"2014","unstructured":"Xu R-X, Li S, Zhang Y, Li X-L, Guo Y-L, Zhu C-G, et al. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids Health Dis. 2014;13:188. https:\/\/doi.org\/10.1186\/1476-511X-13-188.","journal-title":"Lipids Health Dis"},{"issue":"24","key":"843_CR36","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","volume":"127","author":"H Tavori","year":"2013","unstructured":"Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, et al. Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127(24):2403\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001592.","journal-title":"Circulation."},{"issue":"2","key":"843_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/cvr\/cvw053","volume":"110","author":"H Tavori","year":"2016","unstructured":"Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, et al. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc Res. 2016;110(2):268\u201378. https:\/\/doi.org\/10.1093\/cvr\/cvw053.","journal-title":"Cardiovasc Res"},{"key":"843_CR38","doi-asserted-by":"publisher","unstructured":"Pasta A, Cremonini AL, Pisciotta L, Buscaglia A, Porto I, Barra F, et al. PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin Pharmacother. 2020:353\u201363 [published online ahead of print]. https:\/\/doi.org\/10.1080\/14656566.2019.1702970.","DOI":"10.1080\/14656566.2019.1702970"},{"issue":"1","key":"843_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2337\/dc11-1450","volume":"35","author":"S Balducci","year":"2012","unstructured":"Balducci S, Zanuso S, Cardelli P, Salerno G, Fallucca S, Nicolucci A, et al. Supervised exercise training counterbalances the adverse effects of insulin therapy in overweight\/obese subjects with type 2 diabetes. Diabetes Care. 2012;35(1):39\u201341. https:\/\/doi.org\/10.2337\/dc11-1450.","journal-title":"Diabetes Care"},{"issue":"12","key":"843_CR40","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1002\/cam4.1851","volume":"7","author":"T Westphal","year":"2018","unstructured":"Westphal T, Rinnerthaler G, Gampenrieder SP, Niebauer J, Thaler J, Pfob M, et al. Supervised versus autonomous exercise training in breast cancer patients: a multicenter randomized clinical trial. Cancer Med. 2018;7(12):5962\u201372. https:\/\/doi.org\/10.1002\/cam4.1851.","journal-title":"Cancer Med"},{"issue":"8","key":"843_CR41","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.spinee.2019.04.009","volume":"19","author":"M Minetama","year":"2019","unstructured":"Minetama M, Kawakami M, Teraguchi M, Kagotani R, Mera Y, Sumiya T, et al. Supervised physical therapy vs. home exercise for patients with lumbar spinal stenosis: a randomized controlled trial. Spine J Off J North Am Spine Soc. 2019;19(8):1310\u20138. https:\/\/doi.org\/10.1016\/j.spinee.2019.04.009.","journal-title":"Spine J Off J North Am Spine Soc"},{"issue":"1","key":"843_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1123\/jpah.7.1.127","volume":"7","author":"BC Martinson","year":"2010","unstructured":"Martinson BC, Crain AL, Sherwood NE, Hayes MG, Pronk NP, O\u2019Connor PJ. Population reach and recruitment bias in a maintenance RCT in physically active older adults. J Phys Act Health. 2010;7(1):127\u201335. https:\/\/doi.org\/10.1123\/jpah.7.1.127.","journal-title":"J Phys Act Health"},{"issue":"3","key":"843_CR43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/BF03324603","volume":"17","author":"MJG van Heuvelen","year":"2005","unstructured":"van Heuvelen MJG, Hochstenbach JBM, Brouwer WH, de Greef MHG, Zijlstra GAR, van Jaarsveld E, et al. Differences between participants and non-participants in an RCT on physical activity and psychological interventions for older persons. Aging Clin Exp Res. 2005;17(3):236\u201345. https:\/\/doi.org\/10.1007\/BF03324603.","journal-title":"Aging Clin Exp Res"},{"key":"843_CR44","doi-asserted-by":"publisher","unstructured":"\u2022 Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017:e006910. https:\/\/doi.org\/10.1161\/JAHA.117.006910. A landmark systematic review and meta-analysis examining the effect of PCSK9 inhibitors on cardiovascular outcomes.","DOI":"10.1161\/JAHA.117.006910"},{"issue":"10106","key":"843_CR45","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park J-G, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet Lond Engl. 2017;390(10106):1962\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)32290-0.","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"843_CR46","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","volume":"40","author":"L Da Dalt","year":"2019","unstructured":"Da Dalt L, Ruscica M, Bonacina F, Balzarotti G, Dhyani A, Di Cairano E, et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J. 2019;40(4):357\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehy357.","journal-title":"Eur Heart J"},{"issue":"7","key":"843_CR47","doi-asserted-by":"publisher","first-page":"e011581","DOI":"10.1161\/JAHA.118.011581","volume":"8","author":"SU Khan","year":"2019","unstructured":"\u2022 Khan SU, Rahman H, Okunrintemi V, Riaz H, Khan MS, Sattur S, et al. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8(7):e011581. https:\/\/doi.org\/10.1161\/JAHA.118.011581. The latest systematic review and meta-analysis examining the effects of PCSK9 inhibitors on the risk of T2DM.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"843_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4239\/wjd.v8.i7.311","volume":"8","author":"TD Filippatos","year":"2017","unstructured":"\u2022 Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS. PCSK9 and carbohydrate metabolism: a double-edged sword. World J Diabetes. 2017;8(7):311\u20136. https:\/\/doi.org\/10.4239\/wjd.v8.i7.311. A critical article describing the potential effect of PCSK9 inhibitors on glucose metabolism.","journal-title":"World J Diabetes"},{"key":"843_CR49","doi-asserted-by":"publisher","unstructured":"\u2022 Handelsman Y, Lepor NE. PCSK9 Inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: a review. J Am Heart Assoc. 2018;7(13). https:\/\/doi.org\/10.1161\/JAHA.118.008953. A review article describing the potential effect of PCSK9 inhibitors on glucose metabolism.","DOI":"10.1161\/JAHA.118.008953"},{"issue":"Suppl 1","key":"843_CR50","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103\u201323. https:\/\/doi.org\/10.2337\/dc19-S010.","journal-title":"Diabetes Care"}],"updated-by":[{"DOI":"10.1007\/s11883-020-00868-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000}}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00843-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T20:02:02Z","timestamp":1625601722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00843-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00843-x","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"7 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Due to typesetting mistake, an unknown image was accidentally captured as graphical abstract. This should be removed.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"30"}}